Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Amgen and Synaffix sign licensing agreement worth up to $2bn

Amgen will gain access to Synaffix' proprietary antibody-drug conjugates technologies

- PMLiVE

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%

- PMLiVE

WHO reports new Omicron subvariant cases detected in 29 countries worldwide

The new Omicron subvariant is spreading rapidly in the US

- PMLiVE

Jasper Therapeutics’ briquilimab given orphan drug designation in EU

The drug will be used for transplant patients with SCID, AML and MDS

- PMLiVE

The dissemination and consumption of medical literature is evolving

QxMD, part of the WebMD Health Network discusses how they are going to evolve its publication solution, Read by QxMD in 2023.

Medscape Medical Affairs

- PMLiVE

World Antimicrobial Awareness Week 2022

Reports from the World Health Organization show that AMR is one of the top ten threats to global health, causing 1.3 million deaths in 2019

How to Increase Engagement During Virtual Events

Tip #7 - How do you increase engagement during virtual events? Make it fun! ️ See all Top 10 tips: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/

Impetus Digital

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

- PMLiVE

Moderna to acquire OriCiro Genomics for $85m

The deal includes the Japanese DNA supplier’s synthetic biology and enzyme technologies

- PMLiVE

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

First UK proton beam therapy trial launches for certain breast cancer patients

The trial will assess the therapy in patients at risk of heart problems after standard radiotherapy

- PMLiVE

Design considerations and best practices in clinical research

The increased focus on precision medicine in oncology and rare diseases has led to a marked increase of single-arm trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links